this study indicates that the median time of transformation into SMF within a large cohort of 781 progressed patients was 11 years from diagnosis of PV and ET. The MYSEC project discloses a variability of the clinical phenotype of SMF depending by the time to progression from PV or ET. We found that the longer the TTP, the greater the spleen and the lower the hemoglobin. Our study findings basically identify a more advanced phenotype and suggest to carefully monitor these parameters in the management of the chronic phase of PV and ET. CALR genotype is associated to a more slowly progressive disease: this might be a useful information in defining a “genotype-driven” follow up for ET patients.

Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia / Mora B.; Giorgino T.; Guglielmelli P.; Rumi E.; Maffioli M.; Rambaldi A.; Caramella M.; Komrokji R.; Gotlib J.; Kiladjian J.J.; Cervantes F.; Devos T.; Palandri F.; De Stefano V.; Ruggeri M.; Silver R.T.; Benevolo G.; Albano F.; Cavalloni C.; Barraco D.; Pietra D.; Barbui T.; Rotunno G.; Vannucchi A.M.; Passamonti F.. - In: LEUKEMIA RESEARCH. - ISSN 0145-2126. - ELETTRONICO. - 69:(2018), pp. 100-102. [10.1016/j.leukres.2018.04.012]

Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia

Guglielmelli P.;Rotunno G.;Vannucchi A. M.;
2018

Abstract

this study indicates that the median time of transformation into SMF within a large cohort of 781 progressed patients was 11 years from diagnosis of PV and ET. The MYSEC project discloses a variability of the clinical phenotype of SMF depending by the time to progression from PV or ET. We found that the longer the TTP, the greater the spleen and the lower the hemoglobin. Our study findings basically identify a more advanced phenotype and suggest to carefully monitor these parameters in the management of the chronic phase of PV and ET. CALR genotype is associated to a more slowly progressive disease: this might be a useful information in defining a “genotype-driven” follow up for ET patients.
2018
69
100
102
Goal 3: Good health and well-being for people
Mora B.; Giorgino T.; Guglielmelli P.; Rumi E.; Maffioli M.; Rambaldi A.; Caramella M.; Komrokji R.; Gotlib J.; Kiladjian J.J.; Cervantes F.; Devos T....espandi
File in questo prodotto:
File Dimensione Formato  
Mora_LeukemiaResearch2018.pdf

Accesso chiuso

Tipologia: Pdf editoriale (Version of record)
Licenza: Tutti i diritti riservati
Dimensione 531.68 kB
Formato Adobe PDF
531.68 kB Adobe PDF   Richiedi una copia

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1173041
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 13
  • ???jsp.display-item.citation.isi??? 14
social impact